Investigational drugs for the treatment of spinal cord injury: Review of preclinical studies and evaluation of clinical trials from Phase i to II

Narihito Nagoshi, Michael G. Fehlings

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Introduction: Efforts in basic research have clarified mechanisms involved in spinal cord injury (SCI), and resulted in positive findings using experimental treatments including cell transplantation and drug administration preclinically. Based on accumulated results, various clinical trials have begun for human SCI.Areas covered: In this review, the authors focus on five investigational drugs: riluzole, minocycline, Rho protein antagonist, magnesium chloride in polyethylene glycol formulation, and basic fibroblast growth factor. All drugs have established safety and tolerability from Phase I clinical trials, and are now in Phase II. They have been proven to have neuroprotective and/or neuroregenerative effects in animal models of SCI.Expert opinion: To date, diverse drugs have been translated into clinical trials, but none have reached clinical application. A key gap was the lack of reliable biomarkers for SCI to fast-track Phase I/II trials. Furthermore, problems were often due to lack of adequate outcome assessments for both animal models and SCI patients. In order to advance clinical trials more quickly and with greater success, more clinically relevant animal models should be used in basic research. Clinically, it is indispensable to use appropriate outcome measurements and to construct a wide network among clinical centers to validate the efficacy of drugs.

Original languageEnglish
Pages (from-to)645-658
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number5
DOIs
Publication statusPublished - 2015 May 1

Fingerprint

Investigational Drugs
Investigational Therapies
Spinal Cord Injuries
Clinical Trials
Animal Models
Pharmaceutical Preparations
Riluzole
Clinical Trials, Phase I
Minocycline
Magnesium Chloride
Cell Transplantation
Expert Testimony
Fibroblast Growth Factor 2
Research
Biomarkers
Outcome Assessment (Health Care)
Safety
Proteins

Keywords

  • Basic fibroblast growth factor
  • Clinical trials in Phase II
  • Magnesium
  • Minocycline
  • Rho protein antagonist
  • Riluzole
  • Spinal cord injury

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

@article{bb517df50af0495a95a6763a790e6169,
title = "Investigational drugs for the treatment of spinal cord injury: Review of preclinical studies and evaluation of clinical trials from Phase i to II",
abstract = "Introduction: Efforts in basic research have clarified mechanisms involved in spinal cord injury (SCI), and resulted in positive findings using experimental treatments including cell transplantation and drug administration preclinically. Based on accumulated results, various clinical trials have begun for human SCI.Areas covered: In this review, the authors focus on five investigational drugs: riluzole, minocycline, Rho protein antagonist, magnesium chloride in polyethylene glycol formulation, and basic fibroblast growth factor. All drugs have established safety and tolerability from Phase I clinical trials, and are now in Phase II. They have been proven to have neuroprotective and/or neuroregenerative effects in animal models of SCI.Expert opinion: To date, diverse drugs have been translated into clinical trials, but none have reached clinical application. A key gap was the lack of reliable biomarkers for SCI to fast-track Phase I/II trials. Furthermore, problems were often due to lack of adequate outcome assessments for both animal models and SCI patients. In order to advance clinical trials more quickly and with greater success, more clinically relevant animal models should be used in basic research. Clinically, it is indispensable to use appropriate outcome measurements and to construct a wide network among clinical centers to validate the efficacy of drugs.",
keywords = "Basic fibroblast growth factor, Clinical trials in Phase II, Magnesium, Minocycline, Rho protein antagonist, Riluzole, Spinal cord injury",
author = "Narihito Nagoshi and Fehlings, {Michael G.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1517/13543784.2015.1009629",
language = "English",
volume = "24",
pages = "645--658",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Investigational drugs for the treatment of spinal cord injury

T2 - Review of preclinical studies and evaluation of clinical trials from Phase i to II

AU - Nagoshi, Narihito

AU - Fehlings, Michael G.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Introduction: Efforts in basic research have clarified mechanisms involved in spinal cord injury (SCI), and resulted in positive findings using experimental treatments including cell transplantation and drug administration preclinically. Based on accumulated results, various clinical trials have begun for human SCI.Areas covered: In this review, the authors focus on five investigational drugs: riluzole, minocycline, Rho protein antagonist, magnesium chloride in polyethylene glycol formulation, and basic fibroblast growth factor. All drugs have established safety and tolerability from Phase I clinical trials, and are now in Phase II. They have been proven to have neuroprotective and/or neuroregenerative effects in animal models of SCI.Expert opinion: To date, diverse drugs have been translated into clinical trials, but none have reached clinical application. A key gap was the lack of reliable biomarkers for SCI to fast-track Phase I/II trials. Furthermore, problems were often due to lack of adequate outcome assessments for both animal models and SCI patients. In order to advance clinical trials more quickly and with greater success, more clinically relevant animal models should be used in basic research. Clinically, it is indispensable to use appropriate outcome measurements and to construct a wide network among clinical centers to validate the efficacy of drugs.

AB - Introduction: Efforts in basic research have clarified mechanisms involved in spinal cord injury (SCI), and resulted in positive findings using experimental treatments including cell transplantation and drug administration preclinically. Based on accumulated results, various clinical trials have begun for human SCI.Areas covered: In this review, the authors focus on five investigational drugs: riluzole, minocycline, Rho protein antagonist, magnesium chloride in polyethylene glycol formulation, and basic fibroblast growth factor. All drugs have established safety and tolerability from Phase I clinical trials, and are now in Phase II. They have been proven to have neuroprotective and/or neuroregenerative effects in animal models of SCI.Expert opinion: To date, diverse drugs have been translated into clinical trials, but none have reached clinical application. A key gap was the lack of reliable biomarkers for SCI to fast-track Phase I/II trials. Furthermore, problems were often due to lack of adequate outcome assessments for both animal models and SCI patients. In order to advance clinical trials more quickly and with greater success, more clinically relevant animal models should be used in basic research. Clinically, it is indispensable to use appropriate outcome measurements and to construct a wide network among clinical centers to validate the efficacy of drugs.

KW - Basic fibroblast growth factor

KW - Clinical trials in Phase II

KW - Magnesium

KW - Minocycline

KW - Rho protein antagonist

KW - Riluzole

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84927618396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927618396&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.1009629

DO - 10.1517/13543784.2015.1009629

M3 - Review article

C2 - 25645889

AN - SCOPUS:84927618396

VL - 24

SP - 645

EP - 658

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 5

ER -